Elequin Capital’s Travere Therapeutics TVTX Stock Holding History

Elequin Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$909	Sell	16 -13	-45%	-$576	﹤0.01%	580
2026 Q1	$862	Sell	29 -78	-73%	-$2.33K	﹤0.01%	550
2025 Q4	$4.09K	Buy	+107	New	+$3.48K	﹤0.01%	317
2025 Q3	–	Sell	-50	Closed	-$740	–	384
2025 Q2	$740	Buy	+50	New	+$829	﹤0.01%	344
2024 Q4	–	Sell	-462	Closed	-$6.46K	–	635
2024 Q3	$6.46K	Buy	+462	New	+$4.81K	﹤0.01%	275
2024 Q2	–	Sell	-1,430	Closed	-$11K	–	353
2024 Q1	$11K	Buy	1,430 +1,410	+7,050%	+$11.9K	﹤0.01%	90
2023 Q4	$180	Sell	20 -6	-23%	-$44	﹤0.01%	337
2023 Q3	$232	Sell	26 -504	-95%	-$7.11K	﹤0.01%	362
2023 Q2	$8.14K	Buy	+530	New	+$9.64K	﹤0.01%	326
2023 Q1	–	Sell	-7,088	Closed	-$149K	–	523
2022 Q4	$149K	Buy	+7,088	New	+$150K	0.04%	215
2022 Q3	–	Sell	-388	Closed	-$9K	–	676
2022 Q2	$9K	Buy	388 +354	+1,041%	+$8.9K	﹤0.01%	252
2022 Q1	$1K	Buy	+34	New	+$903	﹤0.01%	303

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elequin Capital's TVTX Position: Q2 2026 in Review

Elequin Capital reduced its Travere Therapeutics (TVTX) stake by 45% in Q2 2026, selling an estimated $576 and leaving 16 shares worth $909. The position accounts for ﹤0.01% of the portfolio, ranked #580.

Elequin Capital first reported a position in TVTX in Q1 2022 and has held it in 12 quarters since. The position peaked at $149K in Q4 2022. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Elequin Capital held 16 shares of Travere Therapeutics worth $909 as of Q2 2026.
Elequin Capital sold 13 Travere Therapeutics shares in Q2 2026, an estimated $576.
Travere Therapeutics made up ﹤0.01% of Elequin Capital's portfolio in Q2 2026, its #580 holding.
Elequin Capital first reported a position in Travere Therapeutics in Q1 2022 and has held it in 12 quarters since.
Elequin Capital's Travere Therapeutics position peaked at $149K in Q4 2022.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.